Retina

Robyn Guymer, MBBS, PhD, Deputy Director, Centre for Eye Research Australia, and Professor of Surgery (Ophthalmology), University of Melbourne, Australia, discussed the study findings at the 23rd annual EURETINA Congress in Amsterdam, the Netherlands

We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial"

Dr Ali Erginay of Lariboisière Hospital in Paris, France, discusses his EURETINA presentation, "Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging"

Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.

Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery"

The new range of pure and premixed gases are intended for medium-term use in retinal surgery

Attendees can take advantage of many satellite symposia, sponsored by industry and feauring experts from around the world

Experts in all aspects of retinal care will gather at the RAI Amsterdam Convention Centre, located in the Zuidas business district of the city, which is a short distance from historic Amsterdam with is canals, museums, and shops

The diagnostics company is using AI to screen for diabetic retinopathy, glaucoma and age-related macular degeneration

The AI retinal scanning model will be free to use for all institutions

The nonprofit marked a major milestone by announcing a suite of webinars with Heidelberg Engineering

The diagnostic imaging experts will provide education through the Cybersight platform

The company has 9 presentations at the annual congress of the European Society of Cataract and Refractive Surgeons being held in Vienna. AVG also is a sponsor of the International Society of Presbyopia.

The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.

Reviewing visual and anatomic outcomes in 2 clinical trials

According to the company, the deal expands its European footprint into Spain and Portugal.

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!

"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin, PhD, and Carl Danzig, MD had to say!

Maria H. Berrocal, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium in Marco Island, Florida.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

This intellectual property protects Kiora's pipeline by covering several inflammatory-related therapeutic applications, including posterior non-infectious uveitis.

Researchers have identified markers that indicate the presence of Parkinson disease in patients an average of 7 years before the disease presents clinically.

The first-line treatment to avoid visual impairment for these cases is anti-vascular endothelial growth factor therapy (VEGF).

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Faricimab could lower treatment burden for patients compared to aflibercept

Novel concept: inner choroid/outer retina neurovascular unit

IZERVAY is expected to be available in the United States within 2 to 4 weeks.

At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, shared the latest information on the GALE extension study.

Fernando Arevalo, MD, PhD, FACS, FASRS, shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.